Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Oropharyngeal cancer is a malignant tumor mainly occurring in areas such as the tonsils, base of the tongue, and soft palate. It most commonly affects middle-aged and elderly individuals over 40 years old. Smoking, alcohol abuse, and human papillomavirus (HPV) infection are the primary causes. In recent years, a trend toward younger onset has been observed. There are many treatment options, including immunotherapy, radiotherapy, surgery, and chemotherapy. If not treated in time, it can easily invade surrounding tissues and metastasize to distant sites, leading to serious consequences.
This therapy rebuilds the patient’s immune system, effectively enhancing anti-cancer capacity. It is particularly suitable for patients who have poor tolerance to radiotherapy and chemotherapy or those with recurrent or metastatic disease, representing a cutting-edge treatment approach.
① Activates patient-specific T cells to target and eliminate cancer cells
② Helps eradicate residual lesions and slow disease progression
③ Has minimal side effects, making it suitable for advanced-stage and frail patients
④ Can be combined with other treatments to enhance synergy
④ Helps reduce recurrence rate and improve immune system stability
In clinical practice, cancer patients undergoing surgery, radiotherapy, and chemotherapy often face problems such as impaired immune function, increased infection risk, and slow recovery. To better support patients through treatment, improve tolerance, and enhance quality of life, scientifically staged immune reconstruction plans should be designed for different treatment periods.
● Short-term plan: Rapidly boost immunity through immune cell transfusion to enhance the effect of anti-cancer treatment.
● Mid-term plan: Reduce side effects of conventional treatments, promote physical recovery, and ensure completion of standard therapy.
● Long-term plan: Enhance overall immunity by rebuilding immune cells, intestinal immunity, elemental immunity, and nutritional immunity, thus improving quality of life and prolonging survival.
1. Radiotherapy
Radiotherapy is a core method for treating oropharyngeal cancer, especially for advanced or inoperable patients. Commonly used approaches include image-guided radiotherapy (IGRT) and intensity-modulated radiotherapy (IMRT), which precisely target lesions while minimizing damage to normal tissues, thereby increasing safety. Radiotherapy is also often used postoperatively to eliminate microscopic residual disease.
2. Surgery
Surgical resection is the preferred method for early-stage oropharyngeal cancer, particularly in localized lesions. Depending on tumor location, approaches may include transoral, transcervical, or combined access. Postoperative challenges may involve swallowing and speech function, necessitating thorough preoperative evaluation and postoperative rehabilitation support.
3. Minimally Invasive Surgery
In recent years, minimally invasive surgery has been increasingly applied to oropharyngeal cancer treatment. Common techniques include transoral robotic surgery (TORS) and transoral laser microsurgery (TLM). These approaches cause less trauma, allow faster recovery, and reduce functional impairment compared to traditional surgery, making them suitable for localized early-stage cases.
4. Targeted Therapy
Some oropharyngeal cancers show abnormal expression of epidermal growth factor receptor (EGFR). EGFR inhibitors and other targeted drugs can block cancer cell signaling pathways. This therapy is often combined with radiochemotherapy or used in recurrent disease control to improve overall efficacy.
5. Chemotherapy
Chemotherapy is often used as part of a combined treatment for advanced patients, particularly when administered concurrently with radiotherapy. Typical agents include cisplatin and fluorouracil, which enhance the effects of radiotherapy. Neoadjuvant chemotherapy may also help shrink tumors and improve surgical resection rates.
6. Comprehensive Treatment Strategy
At present, multidisciplinary team (MDT) collaboration is widely applied in oropharyngeal cancer treatment. Individualized plans combine immunotherapy, surgery, radiochemotherapy, nutritional support, and other approaches to maximize disease control, preserve function, and extend survival.
Experts at the United Life International Medical Center emphasize that early intervention and comprehensive management, including immune reconstruction cell therapy, are essential for improving control rates, prolonging survival, and reducing postoperative complications and recurrence risks.
